For decades, limited access to clinical trials has had a direct impact on the development of new medicines, which has remained slow, cost-intensive, and poorly reflective of disease-affected populations.¹ Our vision is to open scientific research to the world using a platform designed for everybody, every biology, everywhere, that accelerates treatments, drives regulatory and clinical decision making, and improves health outcomes. We help bring this vision to life through decentralized clinical trials. In doing so, we help fix one of the largest disparities in healthcare: access to scientific research.
When Medable was formed in 2014, it spent years challenging traditional trial mindsets with a decentralized approach. However, as the pandemic progressed, Medable was instrumental in helping partners rapidly shift from traditional trials to patient-centered strategies no matter their location or therapeutic area.
As a result of this rising tide, we’ve helped our partners execute over 150 decentralized clinical trials, across 80 new therapies, serving over 1 million participants in more than 60 countries. Given these opportunities, we’ve been able to demonstrate why decentralized trials work, helping sponsors cut enrollment timelines by 50% and reducing the amount of sites needed to conduct a trial by 75%. These successes were achieved through the partnership of industry and regulatory leaders like yourself who chose a novel platform that enables remote and hybrid execution of clinical development, from recruitment to study close-out.